FDA Approved: SANDIMMUNE — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approved a supplemental application for SANDIMMUNE (cyclosporine) from Novartis, indicating updated labeling or expanded use via a supplemental approval.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Transplant Rejection
• Kidney Transplant Rejection
• Liver Transplant Rejection
• Plaque Psoriasis

Drugs mentioned

• SANDIMMUNE (CYCLOSPORINE)

Snippet

SUPPL AP for SANDIMMUNE (CYCLOSPORINE)